DSIR Form 3CL / 3CLA: Approval Trail and Year-End Reconciliation

An Indian pharma company running a DSIR-approved in-house R&D centre closes its books for the financial year and turns to the year-end DSIR Form 3CL 3CLA R&D approval reconciliation pharma cascade — the sequence of controls that converts a full year of R&D cost-centre general-ledger entries into a defensible Section 35(2AB) weighted-deduction claim carried into the Return of Income. The regime is a three-form chain: Form 3CM establishes the facility’s DSIR recognition (typically on a three-year renewal cycle); Form 3CL is the year-end quantum certification issued by a DSIR-empanelled Chartered Accountant after auditing the R&D cost-centre expenditure against the DSIR-listed items eligibility criteria; Form 3CLA is the schedule filed alongside the Return of Income disclosing the certified quantum and the weighted-deduction computation. The reconciliation surface is where the accounting cost-centre view of R&D expenditure meets the DSIR eligibility view — and where non-DSIR-listed items mis-tagged as eligible, Form 3CM renewal gaps, and the book-tax gap between Ind AS 38 development-phase capitalisation and Section 35(2AB) revenue-expensed treatment produce the recurring breakages that a tax controller must design against.

The reconciliation in one paragraph

A DSIR-approved pharma R&D facility runs a scientific R&D cost-centre in its accounting general ledger that captures every rupee of expenditure at the facility — scientific staff salaries, consumables (chemicals, reagents, biological materials), clinical trial internal costs, patent filing and prosecution fees, publication charges, and the various admin and capital allocations. Section 35(2AB) of the Income-tax Act 2025 (successor to the same section under the 1961 Act) permits a 100 percent weighted deduction of eligible revenue expenditure at a facility approved by the Department of Scientific and Industrial Research — down from the 150 percent rate applicable till FY 2019-20 and the 200 percent rate applicable till FY 2016-17. The facility approval sits on Form 3CM (issued by the DSIR Secretary, typically valid for three years). The year-end quantum sits on Form 3CL — certified by a DSIR-empanelled Chartered Accountant who audits the R&D cost-centre expenditure against the DSIR-listed items eligibility catalogue set out in Guidelines DSIR/Sec35(2AB)/1/2021. The Form 3CLA schedule, filed alongside the ITR-6 Return of Income, carries the certified eligible quantum and the weighted-deduction computation into the tax filing. The reconciliation cascade — R&D cost-centre general ledger to DSIR-listed items eligibility filter to Form 3CL CA certification to Form 3CLA return schedule to ITR-6 — is the standing year-end control that a pharma tax function runs against the Section 35(2AB) claim. The parallel book control under Ind AS 38 handles the research-phase vs development-phase split and produces the Ind AS 12 deferred-tax computation on the temporary difference between the capitalised-intangible carrying amount and the fully-deducted tax base.

What the scenario looks like in India — safe illustrative brand persona

The Indian pharma sector’s R&D footprint runs across a defined set of DSIR-approved in-house research facilities operated by the major listed formulators, biosimilars players, contract research and manufacturing organisations, and speciality API houses. Illustrative Tier-1 and Tier-2 R&D-heavy players operating DSIR-approved facilities include Sun Pharma’s Innovation Centre, Dr Reddy’s research operations at Bollaram, Cipla, Aurobindo, Lupin, Zydus Cadila’s research centre, Torrent’s new-chemical-entity R&D unit, Alkem’s R&D operations, Glenmark’s discovery research, Biocon Biologics’ research operations, Ajanta Pharma’s Aurangabad R&D centre, Suven Life Sciences and Suven Pharma, Neuland Laboratories, and Divi’s Laboratories. On the CDMO and CRAMS side — where DSIR-approved facilities also feature — the roster includes Piramal Pharma, Laurus Labs, Syngene International (Biocon’s contract research arm), Aragen Life Sciences, and Divi’s Laboratories again for its contract-manufacturing footprint. Clinical trial CROs like Syngene, IQVIA India, Parexel India, Icon Clinical, Lambda Therapeutic Research and Veeda Clinical Research often provide external services that the DSIR-approved facility’s own Form 3CL certification treats under the CRO-linked-to-approved-facility rule.

For the reconciliation persona this article walks through, the reference facility is an illustrative Tier-2 speciality formulator’s R&D centre at Aurangabad — approved by DSIR via a Form 3CM issued in October 2022 with a three-year validity till October 2025, renewed in November 2025 for a further three-year cycle running to November 2028. The centre operates as a distinct scientific R&D cost-centre in the parent company’s general ledger, with dedicated scientific staff, its own consumables register, and its own clinical trial in-house cost pool. The FY 2026-27 year-end reconciliation this article walks through covers the R&D cost-centre trial balance for the twelve months from April 2026 to March 2027, filed as part of the audit-case Return of Income due 31 October 2027 for a company assessee. The Form 3CL year-end certification is scheduled with the DSIR-empanelled Chartered Accountant for July-August 2027 to fit inside the ITR-6 filing timeline.

The regulatory overlay — Section 35(2AB), DSIR guidelines, and the Form 3CM/3CL/3CLA cascade

Section 35(2AB) of the Income-tax Act 2025 — the successor provision to Section 35(2AB) of the Income-tax Act 1961 — is the enabling statute for the weighted deduction. The section provides that where an assessee, being a company engaged in the business of manufacture or production of any article or thing (other than an article or thing specified in the Eleventh Schedule) or in the business of biotechnology, incurs expenditure on scientific research on in-house research and development at a facility approved by the prescribed authority — the Department of Scientific and Industrial Research — a deduction is available at 100 percent of such expenditure. The rate was set at 200 percent till FY 2016-17 and reduced to 150 percent for FY 2017-18 to FY 2019-20 by Finance Act 2016. Finance Act 2020 further reduced the rate to 100 percent from FY 2020-21 onwards. Capital expenditure on plant and machinery at the approved R&D facility is eligible for a separate treatment; land and buildings are expressly excluded from the eligible base regardless of the class of expenditure.

The operational rulebook sits in the DSIR Guidelines for Approval of In-House R&D Centres (reference DSIR/Sec35(2AB)/1/2021 and its predecessor iterations). The guidelines prescribe the full three-form cascade. Form 3CK is the initial application for facility approval — submitted with the R&D infrastructure details, the scientific staff strength, the R&D programme portfolio, and the past-year expenditure track. Form 3CM is the notification of approval issued by the Secretary, DSIR, when the facility clears the recognition threshold — typically with a three-year validity, requiring a renewal application filed 90 to 120 days before expiry so the fresh Form 3CM issues continuously without a lapse window. Form 3CL is the year-end quantum certification by a Chartered Accountant empanelled by DSIR for the certification role — the CA audits the R&D cost-centre expenditure against the DSIR-listed items eligibility catalogue and issues a certified eligible-expenditure figure by category. Form 3CLA is the schedule that the assessee attaches to its Return of Income, disclosing the Form 3CM reference, the Form 3CL certification, the category-wise breakdown, and the weighted-deduction computation.

The DSIR-eligible categories under the guidelines are: scientific research staff salaries (scientists, R&D engineers, technicians, research associates dedicated to the DSIR-approved facility); consumables (chemicals, reagents, biological materials, cell lines, animal-testing consumables); clinical trial in-house costs (patient recruitment, investigator fees for in-house-conducted trials, in-house biomarker analysis); patent filing and prosecution costs; cost of publications; and the DSIR-listed catalogue of scientific instrumentation and reference materials. The non-eligible categories are: land and buildings, civil engineering works, plant and machinery beyond the DSIR-approved list, market research, and testing conducted outside the DSIR-approved facility (samples sent to independent third-party testing houses not covered by the facility’s Form 3CM scope).

The book-parallel to the Section 35(2AB) tax treatment sits under Ind AS 38 (Intangible Assets). Ind AS 38 requires that research-phase expenditure be expensed as incurred, but permits development-phase expenditure to be capitalised as an intangible asset subject to a six-condition test: technical feasibility, intention to complete, ability to use or sell, probable future economic benefits, availability of adequate resources, and reliable measurement of the expenditure. For a pharma R&D programme, the research phase covers early-stage discovery and preclinical work; the development phase covers post-preclinical formulation development, clinical trials where the compound has demonstrated technical feasibility, and process development. Where development-phase costs are capitalised as an intangible on the balance sheet, the mismatch with the fully-deducted Section 35(2AB) tax treatment creates a temporary difference under Ind AS 12 (Income Taxes) and a corresponding deferred tax liability at the applicable corporate rate. The DTL unwinds through P&L in subsequent periods as the intangible amortises.

A worked example — an illustrative Aurangabad R&D centre at FY 2026-27 year-end

Illustrative — the following figures represent the operating pattern of a Tier-2 speciality pharma formulator’s DSIR-approved R&D centre at the scale relevant to Section 35(2AB) claim reconciliation. Public disclosures do not reveal per-facility R&D cost-centre trial balance detail at the granularity below; cross-verify against your own facility’s general-ledger extracts before action.

The formulator’s Aurangabad R&D centre — approved by DSIR via Form 3CM issued October 2022 with three-year validity till October 2025, renewed November 2025 for further three-year cycle to November 2028 — closes its FY 2026-27 R&D cost-centre trial balance with the following category-wise expenditure position:

The R&D cost-centre general-ledger trial balance for FY 2026-27 aggregates to Rs 187.5 crore of revenue expenditure and Rs 68.0 crore of capital expenditure. The reconciliation cascade begins with the R&D controller extracting this trial balance from the accounting system, keyed to the Aurangabad facility’s cost-centre code, and building the DSIR-listed items eligibility filter category by category. The DSIR-eligible revenue expenditure aggregates to Rs 178.0 crore after excluding the Rs 9.5 crore non-eligible pool (civil engineering + market research + external testing + general-purpose IT).

The pre-audit reconciliation pack is presented to the DSIR-empanelled Chartered Accountant appointed for the FY 2026-27 Form 3CL certification. The CA audits each category’s underlying transactions against the DSIR Guidelines DSIR/Sec35(2AB)/1/2021 catalogue — walking through payroll records for the scientific staff line (confirming facility-dedicated attribution rather than corporate-shared allocation), consumables purchase invoices with vendor-and-item verification, clinical trial internal-cost workings with in-house-versus-CRO split evidence, and the DSIR-listed items support against the catalogue reference. On completion of the audit, the CA issues Form 3CL certifying the eligible revenue expenditure at Rs 178.0 crore.

The Form 3CLA return schedule is then prepared for filing alongside the ITR-6 Return of Income. The Form 3CLA discloses: the Aurangabad facility’s Form 3CM approval reference number, the current validity period (November 2025 to November 2028) covering the full FY 2026-27; the Form 3CL certification reference and date; the category-wise eligible expenditure breakdown per the table above; and the Section 35(2AB) weighted-deduction computation — Rs 178.0 crore at 100 percent = Rs 178.0 crore deduction against taxable income. The Form 3CLA and the Form 3CL are attached to the ITR-6 filed by 31 October 2027 (the audit-case deadline for a company assessee for FY 2026-27, i.e. Assessment Year 2027-28).

The Ind AS 38 book treatment runs in parallel. Of the Rs 178.0 crore certified eligible revenue expenditure, the R&D programme classification identifies (illustratively) Rs 46 crore of development-phase expenditure that meets the six-condition test — the formulation development and process development components on programmes past technical-feasibility gate. This Rs 46 crore is capitalised as an intangible asset on the balance sheet and amortises over its useful life. The remaining Rs 132 crore is research-phase (early-stage discovery, preclinical work, and clinical trial phases where technical feasibility is not yet established) and is expensed through P&L. The Section 35(2AB) tax deduction is Rs 178.0 crore in full — irrespective of the book split. The temporary difference is Rs 46 crore (the capitalised intangible carrying amount) against a zero tax base (the expenditure has been fully deducted for tax). At the applicable corporate tax rate — illustratively 25.17 percent for a domestic company under Section 115BAA — the deferred tax liability recognised under Ind AS 12 is Rs 11.58 crore. The DTL unwinds through P&L as the capitalised intangible amortises in subsequent periods.

Common reconciliation breakages

Five breakages recur across DSIR-approved pharma R&D centres running the Section 35(2AB) Form 3CL / 3CLA year-end cascade, and each maps to a specific control failure that a CA pre-audit query, a Form 3CL exclusion, or an income-tax scrutiny assessment will surface.

• Non-DSIR-listed items mis-tagged as eligible expenditure. The most common source of a Form 3CL certification cut is inclusion of civil engineering works (site preparation, building alterations, road works), market research (competitive intelligence, market sizing studies), plant and machinery beyond the DSIR-approved list (general-purpose office equipment, non-scientific IT), and testing conducted outside the DSIR-approved facility (samples sent to independent third-party testing houses not covered by the facility’s Form 3CM scope) in the eligible revenue expenditure pool. Formulators that present an aggregate R&D cost-centre trial balance without a per-line-item DSIR-eligibility tag force the CA to reconstruct the eligibility filter during audit and produce category-wise exclusions that a proper front-loaded reconciliation would have caught. Reconciliation discipline: the DSIR-listed items eligibility flag lives on every purchase register line item at capture, so the year-end extract already carries the eligible-versus-non-eligible split before the CA opens the pack.

• Form 3CM renewal lapse creating retrospective ineligibility. Form 3CM is typically issued with three-year validity and requires a renewal application filed 90 to 120 days before expiry. If the renewal application is delayed and Form 3CM lapses before the fresh notification issues, the R&D facility loses its DSIR-approved status for the lapse window — and revenue expenditure incurred during that window becomes retrospectively ineligible for Section 35(2AB) at scrutiny. If the lapse straddles a financial year-end, the Form 3CL for that year excludes the lapse-window expenditure. If the Return of Income has already claimed the full-year deduction, a scrutiny assessment produces a demand for tax on the disallowed portion plus interest under Section 234B and possibly penalty proceedings under Section 270A. Reconciliation discipline: the Form 3CM validity period is a control field in the R&D cost-centre master; a renewal-application trigger fires 90 to 120 days before expiry.

• Scientific-staff allocation between facility-dedicated and corporate-shared misapplied. The scientific research staff salaries line is DSIR-eligible only for staff dedicated to the approved facility — not for corporate-shared research directors, group-level scientific advisors, or R&D staff whose time is shared between the DSIR-approved facility and a non-approved unit. Formulators that fold the corporate R&D leadership payroll into the facility’s eligible pool without a facility-attribution allocation produce a Form 3CL cut on scrutiny. Reconciliation discipline: the scientific staff master carries a per-employee facility-attribution flag; corporate-shared employees are allocated on a defensible time-share basis with documentary support.

• Clinical trial CRO expenditure treated as in-house without the facility-scope linkage. Clinical trial in-house costs are DSIR-eligible; outsourced CRO expenditure is eligible only if the CRO work is performed under the Form 3CL certification linked to the approved facility — the CRO must operate within the facility’s Form 3CM scope or under an arrangement that the DSIR guidelines permit. Formulators that treat all clinical trial spend (including third-party CRO work at Syngene, IQVIA India, Parexel India, Icon Clinical, Lambda Therapeutic Research, or Veeda Clinical Research) as in-house eligible expenditure produce a certification cut. Companion depth in the clinical trial CRO expenditure Section 35(2AB) eligibility walkthrough covers the in-house-vs-outsourced eligibility mechanic in detail.

• Book-tax gap under Ind AS 38 not tracked separately from the Section 35(2AB) claim. Where the Ind AS 38 development-phase capitalisation and the Section 35(2AB) revenue-expensed tax treatment diverge, the temporary difference produces a deferred tax liability under Ind AS 12 that must be recognised on the balance sheet and unwound as the capitalised intangible amortises. Formulators that treat the Section 35(2AB) deduction as if it aligns with the book expense — without the parallel DTL recognition — under-state the tax liability and over-state distributable reserves. The Ind AS 38 R&D capitalisation vs Section 35(2AB) walkthrough covers the six-condition test application and the DTL computation mechanics.

How a reconciliation platform handles this

A purpose-built pharma reconciliation platform ingests the R&D cost-centre general-ledger extract at year-end, applies the DSIR-listed items eligibility filter per line item against the Guidelines DSIR/Sec35(2AB)/1/2021 catalogue reference, produces the eligible-versus-non-eligible category-wise schedule as a CA pre-audit pack, tracks the Form 3CM validity period against the renewal-trigger calendar, generates the Form 3CLA return schedule draft after Form 3CL certification, and reconciles the Section 35(2AB) tax deduction against the Ind AS 38 book treatment to produce the Ind AS 12 deferred tax liability workings. Match rate improvement of 51 to 88 percent on the line-item eligibility categorisation, combined with an ISO 27001:2022 posture and DPDP Act 2023 aligned data handling, is what makes the platform an infrastructure investment for a pharma R&D-heavy company running a DSIR-approved facility rather than a spreadsheet substitute.

Cross-cluster bridges and where to read next

The Section 35(2AB) claim workflow documented here sits alongside the Wave A cornerstone on the Section 35(2AB) weighted deduction pharma R&D reconciliation guide, which sets the overall regulatory frame for the recognition regime. The Ind AS 38 R&D capitalisation vs Section 35(2AB) walkthrough is the depth reference for the book-tax gap and the six-condition test. The clinical trial CRO expenditure Section 35(2AB) eligibility walkthrough covers the in-house-vs-outsourced CRO expenditure treatment. The methodology framework for building the standing year-end DSIR reconciliation as a repeatable control — with the DSIR-eligibility flag lifecycle-embedded in the R&D purchase register at capture and the Form 3CM validity as a live monitored field — sits in Terra Insight’s own reconciliation failure mode analysis pillar and the reconciliation playbook for monthly close operations pillar. The commercial pillar for the pharma sub-cluster is Pharma reconciliation software India; the broader authority for the platform is reconciliation software India.

The five FAQs below address the operational questions Indian pharma tax controllers and R&D finance leads ask most often when building a standing year-end DSIR Form 3CL / 3CLA reconciliation cascade under the current 100 percent Section 35(2AB) weighted-deduction regime.

Terra Insight Editorial Team Reconciliation Infrastructure

Content authored by practitioners with experience at Amazon India, Intuit QuickBooks, and the Tata Group. Meet the team →

Published 15 July 2026

Domain expertise

TDS Reconciliation GST Input Credit Platform Settlements NACH Batch Matching Bank Reconciliation Form 26AS Matching ERP Integrations Enterprise Finance Ops

Reviewed by

NK

Navin Krishnan

Managing Director & Founder — Terra Insight

Ex Amazon India · Intuit QuickBooks · Tata nexarc

ISO 27001:2022 Patent Pending Incorporated 2024